A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy

Dongwoo Chae, Chung Mo Nam, Joo Hoon Kim, Choong Kun Lee, Seung Seob Kim, Hyo Song Kim, Minkyu Jung, Jae Ho Cheong, Hyun Cheol Chung, Sun Young Rha, Kyungsoo Park

Research output: Contribution to journalArticle

Abstract

The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant kg, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (p = 0.0084) and histologic grade (p = 0.034), and the efficacy of 5-FU with body weight (p < 2e−16) and that of cisplatin with histologic grade (p = 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of kg was associated with a relative risk of 3.19 for PFS (p = 0.00055) and 4.45 for OS (p = 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.

Original languageEnglish
Article number72
JournalAAPS Journal
Volume20
Issue number4
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Stomach Neoplasms
Drug Therapy
Survival
Neoplasms
Fluorouracil
Cisplatin
Disease-Free Survival
Cytostatic Agents
Gastrectomy
Growth
Trastuzumab
Body Weight
Datasets
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Chae, Dongwoo ; Nam, Chung Mo ; Kim, Joo Hoon ; Lee, Choong Kun ; Kim, Seung Seob ; Kim, Hyo Song ; Jung, Minkyu ; Cheong, Jae Ho ; Chung, Hyun Cheol ; Rha, Sun Young ; Park, Kyungsoo. / A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. In: AAPS Journal. 2018 ; Vol. 20, No. 4.
@article{13d2fe9bf1324f4cbc11ce02f288f8a8,
title = "A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy",
abstract = "The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant kg, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (p = 0.0084) and histologic grade (p = 0.034), and the efficacy of 5-FU with body weight (p < 2e−16) and that of cisplatin with histologic grade (p = 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of kg was associated with a relative risk of 3.19 for PFS (p = 0.00055) and 4.45 for OS (p = 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.",
author = "Dongwoo Chae and Nam, {Chung Mo} and Kim, {Joo Hoon} and Lee, {Choong Kun} and Kim, {Seung Seob} and Kim, {Hyo Song} and Minkyu Jung and Cheong, {Jae Ho} and Chung, {Hyun Cheol} and Rha, {Sun Young} and Kyungsoo Park",
year = "2018",
month = "7",
day = "1",
doi = "10.1208/s12248-018-0223-8",
language = "English",
volume = "20",
journal = "AAPS Journal",
issn = "1550-7416",
publisher = "Springer New York",
number = "4",

}

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. / Chae, Dongwoo; Nam, Chung Mo; Kim, Joo Hoon; Lee, Choong Kun; Kim, Seung Seob; Kim, Hyo Song; Jung, Minkyu; Cheong, Jae Ho; Chung, Hyun Cheol; Rha, Sun Young; Park, Kyungsoo.

In: AAPS Journal, Vol. 20, No. 4, 72, 01.07.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy

AU - Chae, Dongwoo

AU - Nam, Chung Mo

AU - Kim, Joo Hoon

AU - Lee, Choong Kun

AU - Kim, Seung Seob

AU - Kim, Hyo Song

AU - Jung, Minkyu

AU - Cheong, Jae Ho

AU - Chung, Hyun Cheol

AU - Rha, Sun Young

AU - Park, Kyungsoo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant kg, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (p = 0.0084) and histologic grade (p = 0.034), and the efficacy of 5-FU with body weight (p < 2e−16) and that of cisplatin with histologic grade (p = 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of kg was associated with a relative risk of 3.19 for PFS (p = 0.00055) and 4.45 for OS (p = 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.

AB - The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant kg, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (p = 0.0084) and histologic grade (p = 0.034), and the efficacy of 5-FU with body weight (p < 2e−16) and that of cisplatin with histologic grade (p = 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of kg was associated with a relative risk of 3.19 for PFS (p = 0.00055) and 4.45 for OS (p = 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.

UR - http://www.scopus.com/inward/record.url?scp=85047877130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047877130&partnerID=8YFLogxK

U2 - 10.1208/s12248-018-0223-8

DO - 10.1208/s12248-018-0223-8

M3 - Article

C2 - 29845329

AN - SCOPUS:85047877130

VL - 20

JO - AAPS Journal

JF - AAPS Journal

SN - 1550-7416

IS - 4

M1 - 72

ER -